2017年ESMO结直肠癌领域研究进展解读——临床实践篇  

Highlights in the field of colorectal cancer comes from 2017 ESMO congress——clinical practice

作　　者：隋红[1] Sui Hong(Medical Department, Harbin Medical University Cancer Hospital, Harbin 150040, China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院内二科,150040

出　　处：《中华结直肠疾病电子杂志》2018年第1期26-31,共6页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：国家自然科学基金青年基金资助项目(No.81201876);黑龙江省青年自然基金项目(No.QC2012C011);黑龙江省博士后基金项目(No.LBH-Z12210);吴阶平医学基金会临床基金项目(No.320.6750.15255)

摘　　要：ESMO(European Society For Medical Oncology)大会是欧洲最具影响力的肿瘤专家年度会议。2017年ESMO大会于2017年9月8日至12日在西班牙马德里举行,大会将癌症研究人员和临床医生聚集在一起,开展合作,交流思想,促进实验室到临床以及从临床到实验室的相互转化。现将会议期间有关结直肠癌领域关注的临床焦点问题:辅助化疗的持续时间、S-1化疗在结直肠癌中的优劣势、围手术期靶向药物选择、靶向治疗的跨线治疗、抗EGFR耐药治疗、肿瘤部位与辅助治疗预后关系做一简要梳理。The ESMO （European Society For Medical Oncology） congress is the most in？uential annual meeting for oncology professionals in Europe.The 2017 ESMO congress was held in Madrid, Spain from 8 th to 12 th September 2017 and brought cancer researchers and clinicians together to enable collaboration and exchange their ideas from the laboratory to the bedside. Here, progress at the cutting edge frontier of colorectal cancer including clinical key points present during the conference will be summarized and some brief comments was given, for example, adjuvant chemotherapy duration, advantages and disadvantages in chemotherapy with S-1, perioperative targeted drug selection,cross-line therapy for targeted therapy,resistance to anti-epidermal growth factor receptor （EGFR） treatment and relationship between location and adjuvant therapy.

关 键 词：结直肠肿瘤 化疗 靶向治疗 S-1 耐药 

分 类 号：R735.34[医药卫生—肿瘤]